by Richard Daverman, PhD
March 26, 2014 -- MicroPort Medical, a China medical device maker headquartered in Shanghai’s Zhangjiang Hi-Tech Park, reported that its third-generation drug eluting stent was recently approved for China marketing. According to MicroPort, the advanced design of the Firehawk® Rapamycin Target Eluting Coronary Stent is effectively inhibits restenosis using only one-third the normal amount of rapamycin, improving its safety. The company intends to market the stent internationally and has applied for European approval. More details....
Stock Symbol: (HK: 853)
Help employers find you! Check out all the jobs and post your resume.
